Expert Interview
A Second Opinion: Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Ticker(s): ICPT, NVO, MDGLInstitution: Washington State University & Liver Institute Northwest
- Professor of Medicine at Washington State University.
- Developed murine models for NASH and is currently exploring the contribution of hepatic iron deposition on the severity of NASH.
- Extensive clinical research interest in all areas of liver disease, ranging from hepatitis C, cholestatic liver disease, PBC, PSC, nonalcoholic steatohepatitis and hepatitis B
- Has authored more than 400 articles, book chapters, reviews and presented his research on liver diseases at more than 150 national and international meetings and scientific symposia.
Potential for new drug therapies in this space?
Added By: dami_adminPlease update us on how field has evolved over past few years.
Importance of liver biopsies for clinical trials and how will this impact commercial opportunities
Has imaging improved ?
Impact of Covid
Which MOA in development is of the highest interest to you and why?
Added By: dami_adminAre combination strategies going to be the best way to treat NASH in the future?
Added By: dami_adminClinical trial failures - Many drugs have flopped in recent years. What have we learned
The GLP-1 agonist Semaglutide had some success and failure in Phase 2 with different stages of disease.
Please provide your interpretation of these conflicting results and your view on potential of this drug class in NASH
Background on clinical practice, how many NASH patients do you manage?
Added By: dami_adminHow is NASH currently diagnosed and treated?
Added By: dami_adminAfter the failure of elafibranor, do you see lanifibranor as differentiated and what do you view as likelihood of its phase 3 success?
Added By: user1ae2bf5fEndpoints of NASH resolution vs. improvement in fibrosis, why do so many drugs achieving robust NASH resolution fail on fibrosis improvement?
View of the Madrigal phase 3 trial design that is looking for NASH resolution and longterm hard outcomes instead of fibrosis stage improvement in short term
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
